Truncated HDAC9 identified by integrated genome-wide screen as the key modulator for paclitaxel resistance in triple-negative breast cancer
Bi Lian, Yu‐Chen Pei, Yi‐Zhou Jiang, Mengzhu Xue, Da‐Qiang Li, Xiaoguang Li, Yi-Zi Zheng, Xiyu Liu, Feng Qiao, Weili Sun, Hong Ling, Min He, Ling Yao, Xin Hu, Zhi‐Ming Shao
Abstract
genetic and cellular analyses elucidated the pivotal role of MITR/MEF2A/IL11 axis in paclitaxel resistance and provided a novel therapeutic strategy for TNBC patients to overcome poor chemotherapy responses.
Topics & Concepts
PaclitaxelCancer researchTriple-negative breast cancerChromatin immunoprecipitationBiologyHistone deacetylaseIn vivoTranscriptomeSmall hairpin RNACancerHistoneBreast cancerGene expressionGene knockdownCell culturePromoterGeneGeneticsHistone Deacetylase Inhibitors ResearchEpigenetics and DNA MethylationCancer Mechanisms and Therapy